# EDGAR Filing Document

**Accession Number:** 0001885827
**File Stem:** 0001193125-26-151292
**Filing Date:** 2026-4
**Character Count:** 4082
**Document Hash:** 0cba3cb5ce7639eae569c98ba495be85
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-151292.hdr.sgml**: 20260410

**ACCESSION NUMBER**: 0001193125-26-151292

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260410

**FILED AS OF DATE**: 20260410

**DATE AS OF CHANGE**: 20260410

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Virax Biolabs Group Ltd
- **CENTRAL INDEX KEY:** 0001885827
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41440
- **FILM NUMBER:** 26855034

**BUSINESS ADDRESS:**
- **STREET 1:** BIOCITY GLASGOW
- **STREET 2:** BO'NESS ROAD, NEWHOUSE
- **CITY:** LANARKSHIRE
- **STATE:** X0
- **ZIP:** ML1 5UH
- **BUSINESS PHONE:** 44 020 7788 7414

**MAIL ADDRESS:**
- **STREET 1:** BIOCITY GLASGOW
- **STREET 2:** BO'NESS ROAD, NEWHOUSE
- **CITY:** LANARKSHIRE
- **STATE:** X0
- **ZIP:** ML1 5UH

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virax Biolabs (Cayman) Ltd
- **DATE OF NAME CHANGE:** 20210930

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br>PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of April 2026**

**Commission File Number: 001-41440**

**Virax Biolabs Group Limited** 

**(Registrant's Name)**

**BioCity Glasgow**

**Bo'Ness Road Newhouse**

**Lanarkshire, ML1 SUH**

**United Kingdom**

**(Address of Principal Executive Offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

When used in this Form 6-K, unless otherwise indicated, the terms "**the Company**," "**Virax**," "**we**," "**us**" and "**our**" refer to Virax Biolabs Group Limited. and its subsidiaries.

**Information Contained in this Form 6-K Report**

**Unregistered Sale of Equity Securities**

As previously reported on Form 6-K filed on December 4, 2025, on December 3, 2025, Virax Biolabs Group Limited (the "Company") entered into a securities purchase agreement with an accredited investor (the "Purchaser") for a private placement offering, pursuant to which the Company received gross proceeds of $5,000,000, before deducting placement agent fees and other offering expenses, in consideration of (i) pre-funded warrants (the "Pre-Funded Warrants") to purchase 12,500,000 ordinary shares, par value $0.001 per share, of the Company (the "Ordinary Shares") and (ii) preferred investment options to purchase up to 12,500,000 Ordinary Shares (the "Preferred Options") at a purchase price of $0.3999 per Pre-Funded Warrant and associated Preferred Option (the "Offering").

The Pre-Funded Warrants have an exercise price of $0.0001 per share, may be exercised commencing on the issuance date and do not expire. The Preferred Options have an exercise price of $0.40 per Ordinary Share and will be exercisable immediately upon issuance for a period of five years from the date of effectiveness of the registration statement referred to below.

As of April 10, 2026, all Pre-Funded Warrants have been exercised, and the total number of the Company's ordinary shares outstanding is 19,923,432.

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | VIRAX BIOLABS GROUP LIMITED |
| Date: | April 10, 2026 | By:  | /s/ James Foster |
|  |  |  | James Foster, Chief Executive Officer |

---

------